Cartesian Therapeutics, Inc. (RNAC)
NasdaqGM · USD · Healthcare · Biotechnology
$6.28 (+1.62%) as of
Key statistics
- Market cap
- 190.00M
- Forward P/E
- -1.65
- EPS (TTM)
- -5.87
- Dividend yield
- 0.00%
- 52-week range
- 5.60 – 11.00
- Beta
- 0.72
- Revenue (TTM)
- 1.48M
- Profit margin
- 0.00%
- Analyst target
- $33.67
- Volume
- 105.63k
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Frederick, MD, United States
- Employees
- 75
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.